Table 1 Baseline, intensive care and hospital characteristics of study patients.
From: Mortality and quality of life in the five years after severe sepsis
| Â | All cases | N = 439 | |
|---|---|---|---|
| Â | Median | 25th | 75th |
Age | 58.0 | 45.0 | 67.0 |
SAPS II score | 41.0 | 30.0 | 54.0 |
SAPS II predicted mortality | 26.6 | 10.6 | 55.3 |
APACHE II score | 23.0 | 17.0 | 28.0 |
APACHE II predictive mortality | 46.0 | 23.6 | 66.5 |
Number of APACHE II comorbidities (median, IQR) | 0 | 0 | 0 |
Number of APACHE II comorbidities (mean, SD) | 0.2 | 0.5 | Â |
Length of hospital stay prior to ICU | 1 | 0 | 3 |
ICU length of stay (all comers) | 7.1 | 2.7 | 15.8 |
ICU length of stay (ICU survivors, n = 277) | 8.8 | 3.9 | 17.9 |
ICU length of stay (ICU non-survivors, n = 162) | 3.9 | 1.3 | 118 |
Hospital length of stay | 19.0 | 8.0 | 41.2 |
| Â | n | % | |
Sex (male) | 234 | 53% | |
Readmission to ICU | 9 | 2% | |
Cardiovascular dysfunction | 237 | 54% | |
Respiratory dysfunction | 282 | 65% | |
Renal dysfunction | 166 | 38% | |
Metabolic acidosis | 195 | 45% | |
Haematological dysfunction | 100 | 23% | |
APACHE II system failure | Â | Â | |
   Respiratory | 138 | 31% | |
   Cardiovascular | 124 | 28% | |
   Neurological | 44 | 10% | |
   Gastrointestinal | 93 | 21% | |
   Other | 26 | 7% | |
   Unknown | 14 | 3% | |
Activated protein C administration | 94 | 21% | |